FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Animal Health Pharma sNADA for Horses OKd

[ Price : $8.95]

Federal Register Final rule: FDA approves an Animal Health Pharmaceuticals supplemental NADA for revised labeling for an oral susp...

Date Confirmed on Baseline Reporting

[ Price : $8.95]

Federal Register Direct final rule: FDA confirms the effective date for a Federal Register final rule removing the requirement for...

One in Eight Approval Actions Require a REMS: Axelrad

[ Price : $8.95]

CDER associate director for policy Jane Axelrad tells an industry conference that about one in eight approval actions taken since ...

Waxman Questions FDAs Legal Priorities Favoring Industry

[ Price : $8.95]

House Government Reform and Oversight committee chair Henry Waxman seeks answers from FDA after an internal e-mail suggests that p...

Further Study Needed for Gilead CF Drug

[ Price : $8.95]

FDA says Gilead Sciences must conduct another clinical trial on its investigation cystic fibrosis drug aztreonam lysine.

Approval Sought for New Azor Indication

[ Price : $8.95]

Daiichi Sankyo files an sNDA for its Azor as initial hypertension therapy in patients likely to need multiple drugs to meet blood ...

Senate Committee Looks at Device Ads

[ Price : $8.95]

CDRH director Daniel Schultz tells a Senate committee there are significant regulatory differences and requirements between DTC ad...

CDRH Presentation Incorrect on Enforcement

[ Price : $8.95]

CDRH corrects an erroneous enforcement statistic presented by director Dan Schultz at a RAPS session in Boston 9/15.

Carcinogenicity Study Dose Selection Guidance

[ Price : $8.95]

FDA issues an ICH guidance to help sponsors select appropriate doses for rodent carcinogenicity studies.

Appeals Court Lifts Risperdal Exclusivity

[ Price : $8.95]

An appeals court panel says Teva is not entitled to marketing exclusivity for generic Risperdal in a patent-listing dispute.